Indian drug maker Claris Lifesciences Ltd. has initiated the sale of its U.S. injectable-drug business, which could be worth at least $500 million, according to a Bloomberg article.
Claris is said to have asked for bids from large U.S. companies such as Baxter International by the end of August, according to sources. The sale could also draw interest from Indian companies such as Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd. and Torrent Pharmaceuticals Ltd., the article said.
Read the full story